BioCryst Pharmaceuticals (Nasdaq: BCRX) is consolidating its operations by moving the company’s headquarters to Durham from Birmingham, Ala.

Jon Stonehouse, the firm’s chief executive officer, told the that between 10 and 15 jobs would be affected and another eight positions will be eliminated.

The firm employs some 50 people with 30 located at its Durham research and development operation.

“We feel BioCryst is in one of the strongest positions since I’ve been here,” Stonehouse said, according to the newspaper. “We’re absolutely working towards our goal as an enduring and efficient company.”

BioCryst produces the flu treatment Peramivir.

Get the latest news alerts: at Twitter.